Prim, S.A. (BME:PRM)
Spain
· Delayed Price · Currency is EUR 11.55
-0.15 (-1.28%)
Jun 27, 2025, 9:44 AM CET
Prim, S.A. Revenue
In the year 2024, Prim, S.A. had annual revenue of 233.36M EUR with 7.73% growth. Prim, S.A. had revenue of 113.67M in the half year ending December 31, 2024, with 15.49% growth.
Revenue
233.36M
Revenue Growth
+7.73%
P/S Ratio
0.85
Revenue / Employee
243.59K
Employees
958
Market Cap
199.06M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 233.36M | 16.74M | 7.73% |
| Dec 31, 2023 | 216.62M | 19.22M | 9.74% |
| Dec 31, 2022 | 197.40M | 28.82M | 17.10% |
| Dec 31, 2021 | 168.57M | 21.16M | 14.35% |
| Dec 31, 2020 | 147.41M | -3.66M | -2.42% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Grifols | 7.37B |
| Laboratorios Farmaceuticos Rovi | 767.47M |
| Almirall | 1.03B |
| Faes Farma | 524.02M |
| Pharma Mar | 175.75M |
| Clínica Baviera | 279.53M |
| Laboratorio Reig Jofre | 340.41M |
| Oryzon Genomics | 7.36M |